Aignostics Promotes Atlas H&E-TME Access for Academic and Biopharma Users

According to a recent LinkedIn post from Aignostics, the company engaged extensively with researchers and collaborators during the AACR 2026 conference in San Diego and drew interest to its Atlas for Academics program. The post highlights two access routes for academic users of its Atlas H&E-TME digital pathology platform: OpenTME, an open-access TCGA-based dataset, and a Research Access Program enabling use of researchers’ own slides.

The same post indicates that Aignostics is also targeting biopharma clients by offering free pilots of Atlas H&E-TME, suggesting a push to expand commercial evaluation and potential adoption within drug development workflows. For investors, this dual focus on academic uptake and biopharma pilots may signal an effort to broaden data usage, validate the technology in real-world settings, and build a future pipeline of paying enterprise customers in AI-driven digital pathology.